| Literature DB >> 28978041 |
Lei Guo1, Shi-Bin Chao2,3, Lu Xiao4, Zhen-Bo Wang2,5, Tie-Gang Meng2,4, Yuan-Yuan Li2, Zhi-Ming Han2, Ying-Chun Ouyang2, Yi Hou2, Qing-Yuan Sun2,5, Xiang-Hong Ou1.
Abstract
Recently, numerous studies have reported that the mature sperm contains both coding and non-coding RNAs and the sperm delivers some RNAs to the oocyte at fertilization. However, the functions of the RNAs carried to the oocyte by sperm at fertilization in embryonic development remains a mystery. In this study, the mature spermatozoa were treated with lysolecithin, pronase and RNases (RNase A and RNase H) to remove the sperm-carried RNAs, and then injected into normal mature oocyte. The results showed that after the treatment, the content of the sperm RNAs was decreased by about 90%. The blastocyst formation rate and the live birth rate of the embryos from intracytoplasmic sperm injection (ICSI) using the treated sperm were significantly decreased (P<0.01), while these effects were partially rescued by injecting total wide-type sperm RNAs. The reproductive capacity of offspring (F0) in sperm-treated group was similar with that in control group (P>0.05), but the body weight of F1 mice from sperm-treated group was lower than that in control group after two weeks of birth (P<0.05). These results demonstrated that the sperm-carried RNAs have important roles in embryonic development.Entities:
Keywords: RNase; blastocyst formation; intracytoplasmic sperm injection; offspring; sperm RNA
Year: 2017 PMID: 28978041 PMCID: PMC5620181 DOI: 10.18632/oncotarget.18672
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Analysis of RNA-seq data from the sperm with or without LL+P+RNases-treatment
(A) Distribution of RPKM from the sperm with or without treatment. (B) Heat maps derived from cluster analysis of RNA-seq from the sperm with or without treatment. (C) The gene ontology analysis of the differentially expressed RNAs from the sperm with or without treatment.
The ontological categories of different expressive transcripts associated with embryonic cleavage, blastocyst formation, blastocyst development and blastocyst growth
| GO term | Description | No. of genes | Genes |
|---|---|---|---|
| GO:0040016 | embryonic cleavage | 6 | Cullin-3, Protein AATF, DNA topoisomerase 2-alpha,Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, DNA topoisomerase 1, TFIIH basal transcription factor complex helicase XPD subunit |
| GO:0001825 | blastocyst formation | 30 | 14 kDa phosphohistidine phosphatase, Adenosine deaminase, B-cell lymphoma/leukemia 10, Butyrophilin subfamily 2 member A2, Butyrophilin-like protein 2, C-C chemokine receptor type 7, CKLF-like MARVEL transmembrane domain-containing protein 3, CMRF35-like molecule 8, Dual specificity protein phosphatase 22, E3 ubiquitin-protein ligase CBL-B, ETS-related transcription factor Elf-1, Fc receptor-like protein 5, Germinal center-associated signaling and motility protein, Intermediate conductance calcium-activated potassium channel protein 4, Leupaxin, Mucosa-associated lymphoid tissue lymphoma translocation protein 1 homolog, NFAT activation molecule 1, Protein TESPA1, Receptor-type tyrosine-protein phosphatase C, Roquin-1, Serine/threonine-protein kinase D2, Signal-transducing adaptor protein 1, Thy-1 membrane glycoprotein, Transcription factor Sp1, Tyrosine-protein kinase Lyn, Tyrosine-protein phosphatase non-receptor type 2, Tyrosine-protein phosphatase non-receptor type 6, Ubiquitin-associated and SH3 domain-containing protein A, Voltage-dependent L-type calcium channel subunit alpha-1F, Zona pellucida sperm-binding protein 3 |
| GO:0001824 | blastocyst development | 61 | 60S ribosomal protein L7-like 1, Activin receptor type-1C, Adenosine deaminase, BCL2/adenovirus E1B 19 kDa protein-interacting protein 2, Breast cancer type 2 susceptibility protein homolog, Bromodomain-containing protein 4, Bystin, Cbp/p300-interacting transactivator 2, CCR4-NOT transcription complex subunit 1, CCR4-NOT transcription complex subunit 3, Condensin-2 complex subunit G2, Deleted in malignant brain tumors 1 protein, DNA endonuclease RBBP8, DNA repair protein RAD51 homolog 2, DNA replication complex GINS protein PSF1, DNA replication complex GINS protein SLD5, Eomesodermin homolog, ETS translocation variant 2, Forkhead box protein D3, G2/M phase-specific E3 ubiquitin-protein ligase, Heart- and neural crest derivatives-expressed protein 1, Hepatocyte nuclear factor 1-alpha, Histone-lysine N-methyltransferase SETDB1, Homeobox protein CDX-2, Homeodomain-only protein, HORMA domain-containing protein 1, Integrator complex subunit 1, Lysine-specific demethylase 4C, Mediator of RNA polymerase II transcription subunit 21, Methylcytosine dioxygenase TET1, NEDD4-binding protein 2-like 2, Nodal, Notchless protein homolog 1, Nuclear autoantigenic sperm protein, Nuclear distribution protein nudE-like 1, Partner and localizer of BRCA2, POU domain class 5 transcription factor 1, Pre-mRNA-processing factor 19, Pre-mRNA-splicing factor SYF1, Proheparin-binding EGF-like growth factor, Ribosomal RNA small subunit methyltransferase NEP1, RNA polymerase-associated protein RTF1 homolog, Sal-like protein 4, Serine/threonine-protein kinase Nek2, Ski-like protein, Splicing factor 3B subunit 6, Steroid hormone receptor ERR2, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1, THO complex subunit 2, THO complex subunit 5 homolog, Transcription factor AP-2 gamma, Transcription factor SOX-17, Transcription factor Sp1, Transcription factor Sp3, Transcription factor Spi-C, Transforming growth factor beta receptor type 3, Upstream-binding factor 1-like protein 1, WD repeat-containing protein 74, Zinc finger protein 830, Zinc finger protein ZPR1, Zona pellucida sperm-binding protein 3 |
| GO:0001832 | blastocyst growth | 21 | Activin receptor type-1C, Breast cancer type 2 susceptibility protein homolog, Bromodomain-containing protein 4, Condensin-2 complex subunit G2, Deleted in malignant brain tumors 1 protein, DNA repair protein RAD51 homolog 2, DNA replication complex GINS protein PSF1, DNA replication complex GINS protein SLD5, Histone-lysine N-methyltransferase SETDB1, Integrator complex subunit 1, Nuclear distribution protein nudE-like 1, Partner and localizer of BRCA2, POU domain class 5 transcription factor 1, Pre-mRNA-processing factor 19, Proheparin-binding EGF-like growth factor, RNA polymerase-associated protein RTF1 homolog, Sal-like protein 4, Steroid hormone receptor ERR2, Upstream-binding factor 1-like protein 1, Zinc finger protein 830, Zinc finger protein ZPR1 |
Preimplantation development of embryos derived from ICSI using WT oocytes and LL+P+RNases-treated sperm with or without total WT sperm RNA
| No. of oocytes injected | Number of embryos at each stage | |||||
|---|---|---|---|---|---|---|
| 2PN(% of total) | 2-cell(% of 2PN) | 4-8-cell(% of 2-cell) | Morula(% of 2-cell) | Blastocyst(% of 2-cell) | ||
| Control | 156 | 151 (96.79) | 125 (82.78) | 116 (92.80) | 102 (81.60) | 70 (56.00) |
| LL+P+RNases-treated | 227 | 218 (96.04) | 177 (81.19) | 161 (90.96) | 139 (78.53) | 28 (15.82)**, ## |
| LL+P+RNases-treated + WT sperm RNA | 82 | 77 (93.9) | 67 (87.01) | 61 (91.04) | 56 (83.58) | 27 (40.30) |
** LL+P+RNases-treated group VS control group, P < 0.01.
## LL+P+RNases-treated + WT sperm RNA group VS LL+P+RNase-treated group, P < 0.01.
Term development of mouse embryos developed from the oocytes fertilized by injection of LL+P+RNases-treated sperm with or without total WT sperm RNA
| No. of 2-cell embryos transferred (No. of recipients) | No. of live offspring at term (%) | |
|---|---|---|
| Control | 60 (4) | 22 (36.67) |
| LL+P+RNases-treated | 187 (10) | 6 (3.21)**, ## |
| LL+P+RNases-treated + WT sperm RNA | 86 (5) | 17 (19.77) |
** LL+P+RNases-treated group VS control group, P < 0.01.
## LL+P+RNases-treated + WT sperm RNA group VS LL+P+RNase-treated group, P < 0.01.
Figure 2Histone modifications of the late 1-cell stage embryos derived from ICSI using the sperm with or without LL+P+RNases-treatment
(A) H3K27me3 in the late 1-cell stage embryos derived from ICSI using the sperm with or without treatment (n = 18). The staining pattern of H3K27me3 in the late 1-cell stage embryos derived from ICSI using the sperm with or without treatment (a) and the ratio of H3K27me3/DNA signal intensity in the late 1-cell stage embryos derived from ICSI using the sperm with or without treatment (b). H3K27me3: green; DNA: blue. Bar=20μm. (B) H3K4me3 in the late 1-cell stage embryos derived from ICSI using the sperm with or without treatment (n = 20). The staining pattern of H3K4me3 in the late 1-cell stage embryos derived from ICSI using the sperm with or without treatment (a) and the ratio of H3K4me3/DNA signal intensity in the late 1-cell stage embryos derived from ICSI using the sperm with or without treatment (b). H3K4me3: green; DNA: blue. Bar=20μm. (C) H3K14ac in the late 1-cell stage embryos derived from ICSI using the sperm with or without treatment (n = 19). The staining pattern of H3K14ac in the late 1-cell stage embryos derived from ICSI using the sperm with or without treatment (a) and the ratio of H3K14ac/DNA signal intensity in the late 1-cell stage embryos derived from ICSI using the sperm with or without treatment (b). H3K14ac: green; DNA: blue. Bar=20μm. (D) H4K12ac in the late 1-cell stage embryos derived from ICSI using the sperm with or without treatment (n = 18). The staining pattern of H4K12ac in the late 1-cell stage embryos derived from ICSI using the sperm with or without treatment (a) and the ratio of H4K12ac/DNA signal intensity in the late 1-cell stage embryos derived from ICSI using the sperm with or without treatment (b). H4K12ac: green; DNA: blue. Bar=20μm.
Figure 3Histone modifications of the 2-cell stage embryos derived from ICSI using the sperm with or without LL+P+RNases-treatment
(A) H3K27me3 in 2-cell stage embryos derived from ICSI using the sperm with or without treatment (n = 20). The staining pattern of H3K27me3 in 2-cell stage embryos derived from ICSI using the sperm with or without treatment (a) and the ratio of H3K27me3/DNA signal intensity in 2-cell stage embryos derived from ICSI using the sperm with or without treatment (b). H3K27me3: green; DNA: blue. Bar=20μm. (B) H3K4me3 in 2-cell stage embryos derived from ICSI using the sperm with or without treatment (n = 18). The staining pattern of H3K4me3 in 2-cell stage embryos derived from ICSI using the sperm with or without treatment (a) and the ratio of H3K4me3/DNA signal intensity in 2-cell stage embryos derived from ICSI using the sperm with or without treatment (b). H3K4me3: green; DNA: blue. Bar=20μm. (C) H3K14ac in 2-cell stage embryos derived from ICSI using the sperm with or without treatment (n = 21). The staining pattern of H3K14ac in 2-cell stage embryos derived from ICSI using the sperm with or without treatment (a) and th ratio of H3K14ac/DNA signal intensity in 2-cell stage embryos derived from ICSI using the sperm with or without treatment (b). H3K14ac: green; DNA: blue. Bar=20μm. (D) H4K12ac in 2-cell stage embryos derived from ICSI using the sperm with or without treatment (n = 17). The staining pattern of H4K12ac in 2-cell stage embryos derived from ICSI using the sperm with or without treatment (a) and the ratio of H4K12ac/DNA signal intensity in 2-cell stage embryos derived from ICSI using the sperm with or without treatment (b). H4K12ac: green; DNA: blue. Bar=20μm.
The reproductive capacity of F0 mice
| No. of mice examined | No. of total litters | No. of offspring per litter | ||
|---|---|---|---|---|
| Female | control | 3 | 19 | 8.21±0.37 |
| LL+P+RNases-treated | 3 | 18 | 7.72±0.38 | |
| Male | control | 3 | 20 | 8.11±0.21 |
| LL+P+RNases-treated | 3 | 18 | 7.89±0.43 |
Figure 4The body weight trajectories of F1 males (A) and females (B). * P<0.05.